Overall, the triple therapy (IL-2/14d) effectively enhanced T cell infiltration in pancreatic cancer compared to CAR T cells alone, presumably by reducing the immunosuppressive characteristics of the TME. Here, IL2 is linked to familial pancreatic carcinoma.